European stocks of GlucaGen injections have been limited due to a manufacturing process problem that has now been resolved. The shortage is unlikely to affect people with diabetes directly.
There are no quality implications for GlucaGen already in the supply chain, either in the UK or any other market.
Despite there being a shortage in Europe, Novo Nordisk has assured Diabetes UK it does have stock in its UK warehouse.
As a precautionary measure Novo Nordisk is limiting supply to wholesalers to prevent inadvertent depletion of stocks.
Maintaining safety stock
Novo Nordisk does have stocks in the UK and is implementing internal procedures in order to maintain a safety stock at their warehouse. Stock will not be sold to wholesalers, but kept in reserve to supply against patient prescriptions should the need arise.
It is not anticipated to take longer than a few months for Novo Nordisk to replenish their stockpiles.
Any dispensing points requiring a direct order service from Novo Nordisk because their supplier cannot send them stocks should contact Novo Nordisk directly on their customer Careline – 0845 600 5055.
Novo Nordisk has confirmed they are able to meet demand in the UK at present.